Skip to main content

Table 3 Summary of adverse events

From: Transhepatic arterial infusion chemotherapy using a combination of miriplatin and CDDP powder versus miriplatin alone in the treatment of hepatocellular carcinoma: a randomized controlled trial

Number of sessions TOCE TOCE + HAIC
15 36
Grade
Haematological toxicity 1 2 3 4 1 2 3 4
White blood cell decreased 2 0 0 0 0 0 0 0
Neutrophil count decreased 2 0 0 0 0 0 0 0
Platelet count decreased 0 0 0 0 0 0 0 0
Anemia 0 0 0 0 0 0 0 0
Non-haematological toxicity 1 2 3 4 1 2 3 4
AST increased 3 0 0 0 0 0 0 0
ALT increased 3 0 0 0 0 0 0 0
Blood bilirubin increased 0 0 0 0 0 0 0 0
PT-INR increased 0 0 0 0 0 0 0 0
Hypoalbuminemia 0 0 0 0 2 0 0 0
Creatinine increased 0 0 0 0 0 0 0 0
Anorexia 0 0 0 0 3 0 0 0
Nausea 2 0 0 0 0 0 0 0
Vomiting 0 0 0 0 0 0 0 0
Fever 1 0 0 0 5 0 0 0
Diarrhea 0 0 0 0 0 0 0 0
Fatigue 0 0 0 0 0 0 0 0
Alopecia 0 0 0 0 0 0 0 0
Urticaria 0 0 0 0 0 0 0 0
Abdominal pain 1 0 0 0 0 0 0 0
  1. TOCE transarterial oily chemoembolization, TACE transarterial chemoembolization, HAIC hepatic arterial infusion chemotherapy, PT-INR prothrombin time-international normalized ratio